TL;DR
Get pet supplies delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
IDEXX, Elanco and Zoetis are investing in pet cancer diagnostics and treatments, while companies also pursue therapies for chronic kidney disease. The moves come as competition in dog dermatology intensifies and recent financial results differ across the companies. Some products remain in development, and timelines and commercial outcomes are not yet certain.
IDEXX Laboratories, Elanco and Zoetis are pursuing growth in pet cancer diagnostics and treatments and chronic kidney disease therapies, executives said at recent healthcare conferences. Their plans point to expanding investment in complex conditions even as competition in dog dermatology intensifies and company results remain mixed.
IDEXX is expanding its Cancer Dx platform, which launched with testing for lymphoma. CEO Mike Erickson said the initial tests can detect lymphoma up to eight months before clinical signs, with what he described as more than 99% specificity and 79% sensitivity. The company plans a multi-cancer panel for lymphoma, mast cell tumors and hemangiosarcoma, which Erickson said together account for 40% of cancers in dogs. IDEXX expects the panel to be available by the end of 2026, according to the report.
Elanco and Zoetis also identified oncology as an opportunity. Elanco CEO Jeff Simmons said the company is seeking a broad-spectrum cancer product that could be offered at a cost-effective price. Zoetis already sells Palladia for cutaneous mast cell tumors in dogs. CEO Kristin Peck said owners are testing pets for cancer even when treatment is unavailable, and that future medicines would need to be safe for use by general-practice veterinarians. She said Zoetis has two oncology products in its pipeline.
Kidney disease is another focus. Elanco’s Simmons cited estimates that one-quarter to one-third of cats may develop renal failure. Peck said Zoetis is working on multiple products, diagnostics and biomarkers for chronic kidney disease, including a candidate intended to slow disease progression and prevent kidney damage. She said the company is targeting approval by the end of 2027; other work is aimed at symptoms of later-stage disease.
Cancer and Kidney Care Draw Investment
Investment in cancer testing and kidney disease treatments could expand options for veterinarians and pet owners dealing with conditions that can be difficult to detect or manage. IDEXX’s planned multi-cancer panel would broaden its diagnostic offer beyond lymphoma, while Zoetis is pursuing both disease-progression and symptom-focused approaches to kidney disease. These are company development plans, not evidence that the products are already available or that they will change clinical outcomes.
The commercial stakes are also tied to whether owners can access and afford new care. Elanco’s Simmons described demand for cost-efficient oncology products, while Zoetis’s Peck emphasized safety in general veterinary practice. The companies’ strategies show that market growth depends not only on scientific development, but also on clinical usability, pricing and access.
As an affiliate, we earn on qualifying purchases.
Dermatology Competition Shapes Strategy
The expansion into other treatment areas is occurring alongside a contest in the established dog dermatology market. Elanco said its once-daily allergy and atopic dermatitis treatment Zenrelia was its largest contributor to global growth in the second quarter. Simmons said the international dermatology market grew 9% in the first half of 2026 and cited gains for Zenrelia in Brazil and Europe. Those figures and explanations are company statements.
Zoetis, whose dermatology portfolio includes Apoquel and Cytopoint, said new competition was affecting categories where it previously held leading positions. Peck said the company expects U.S. approval for long-acting Cytopoint Plus by the end of 2026 and cited patent protection for some products through 2032. The financial picture is mixed: IDEXX reported 11% year-over-year growth in recurring revenue for its Companion Animal Group diagnostics in the second quarter, supported by increased utilization, while Zoetis reported lower sales amid what it called a more pressured companion animal market. Elanco reported strong second-quarter growth.
“These are 3 of the most common and most dangerous cancers, covering 40% of all the cancers in dogs.”
— IDEXX CEO Mike Erickson, as reported by GlobalPETS
Product Timelines and Access Remain Open
The proposed cancer panel, Zoetis’s oncology candidates and its kidney disease products are at different development stages. The report does not provide detailed trial results, regulatory submissions or independent evidence for the companies’ market estimates and product performance claims. IDEXX’s expected panel timing and Zoetis’s target approval date are company expectations, not guarantees.
It is also unclear how much new treatments will cost, whether insurance or veterinary-care access will limit uptake, and how broadly general-practice clinics could use future cancer medicines. The reported sales results do not establish how much each product or market contributed to overall company performance beyond the figures and explanations attributed to executives.
Development and Approvals Ahead
The next milestones identified by the companies are IDEXX’s expected multi-cancer panel launch by the end of 2026, Zoetis’s target for U.S. approval of Cytopoint Plus by year-end 2026, and a target approval by the end of 2027 for a Zoetis kidney disease candidate. Those dates remain subject to development and regulatory progress. Further trial data, regulatory updates and financial reporting should clarify whether the planned products reach the market and how they perform.
Key Questions
Which companies are expanding into pet cancer care?
IDEXX, Elanco and Zoetis described cancer diagnostics or treatment development as areas of interest. Their plans range from an expanded diagnostic panel to oncology products in development.
When does IDEXX expect its multi-cancer panel to be available?
IDEXX CEO Mike Erickson said the company expects the panel to be available by the end of 2026. This is a company target, not a confirmed launch date.
What kidney disease work is Zoetis pursuing?
Zoetis says it is developing products, diagnostics and biomarkers for chronic kidney disease. One candidate is intended to slow disease progression and prevent kidney damage, with the company targeting approval by the end of 2027.
What is happening in the dog dermatology market?
Elanco reported growth for Zenrelia, while Zoetis said new competition was affecting established categories, including Apoquel. Zoetis expects U.S. approval for long-acting Cytopoint Plus by the end of 2026, subject to regulatory review.
Are the cancer and kidney products already available?
Not all of them. Palladia is an existing Zoetis treatment for cutaneous mast cell tumors in dogs, but the multi-cancer panel and the other products discussed are planned or in development. The report does not establish that those candidates have received approval.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
